AKT1 and neoplasm: Inhibition of the PI3K/Akt pathway by NVP-BEZ235 activates androgen receptor signaling by relieving feedback inhibition of Her2 kinases [83, 84], thus maintaining tumor cell growth in PTEN-deficient murine prostate cancer models.